📉 The Financial Deep Dive
Anthem Biosciences announced its un-audited consolidated financial results for Q3FY26, revealing a mixed performance characterized by a significant revenue contraction juxtaposed with robust margin expansion.
The Numbers:
- Revenue: Consolidated revenue from operations declined by 15.0% year-on-year (YoY) to ₹4,232 Mn in Q3FY26, down from ₹4,978 Mn in Q3FY25. This decline was primarily driven by the CRDMO segment, which saw a 19.4% decrease, while the Specialty Ingredients segment managed a modest 6.7% growth.
- EBITDA: Despite the revenue dip, EBITDA saw a marginal increase of 3.7% YoY, reaching ₹1,907 Mn in Q3FY26.
- EBITDA Margin: This growth was propelled by a significant expansion in EBITDA margins, which improved to 41.8% in Q3FY26 from 35.2% in Q3FY25, indicating enhanced operational efficiency and cost management.
- PAT: Profit After Tax (PAT) declined by 25.3% YoY to ₹928 Mn in Q3FY26. PAT margins stood at 20.3% for the quarter.
- Exceptional Item: An exceptional item of ₹254 Mn was recorded in Q3FY26, primarily due to the impact of newly notified Labour Codes by the Government of India, which affected the PAT.
- Revenue: Consolidated revenue grew by 11.2% YoY to ₹15,134 Mn.
- EBITDA: Increased by 22.6% YoY to ₹6,712 Mn, with margins improving to 41.5%.
- PAT: Rose by 9.1% YoY to ₹4,020 Mn, with margins at 24.8%.
The key takeaway from the quarterly results is the company's ability to expand its profitability margins even as revenue declined. This suggests effective cost control and a focus on higher-margin business. The strong net cash position of ₹12,312 Mn as of December 31, 2025, provides financial strength and flexibility.
The Grill:
While the provided text does not detail a specific 'grill' from analysts, the management's commentary addressed the quarterly performance. The Chairman, MD & CEO acknowledged the revenue influence from a higher base in the previous year, while highlighting margin improvement as a key compensating factor. The management expressed confidence for a strong fiscal year-end driven by robust underlying demand, implicitly addressing potential investor concerns over the revenue dip.
Risks & Outlook:
The primary risk highlighted is the dependence on the CRDMO segment, which experienced a notable YoY decline. Investors will be keen to understand the sustainability of this trend and the drivers behind the Specialty Ingredients segment's growth. The exceptional item impacting PAT also warrants attention, though it is noted as a one-off due to regulatory changes.
The management's outlook remains positive, with confidence in delivering a strong finish to the financial year, underpinned by robust demand. The focus will be on how Anthem Biosciences can translate this demand into revenue growth while maintaining its improved margins in the upcoming quarters.